Geulah Livshits
Stock Analyst at Chardan Capital
(4.50)
# 310
Out of 5,015 analysts
223
Total ratings
49.78%
Success rate
26.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Maintains: Buy | $15 → $17 | $8.24 | +106.31% | 11 | Oct 7, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $60 → $73 | $69.90 | +4.43% | 3 | Sep 26, 2025 | |
| IMRX Immuneering | Maintains: Buy | $13 → $20 | $6.13 | +226.26% | 14 | Sep 26, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $219 → $216 | $181.47 | +19.03% | 13 | Aug 22, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 | $3.42 | +221.64% | 21 | Aug 20, 2025 | |
| MGX Metagenomi | Maintains: Buy | $12 → $11 | $2.86 | +284.62% | 7 | Aug 15, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $15 | $5.96 | +151.68% | 8 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $9 → $10 | $4.88 | +104.92% | 14 | Aug 12, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $25 | $8.90 | +180.90% | 12 | Aug 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $68 → $60 | $24.52 | +144.70% | 15 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $10 | $5.68 | +76.06% | 6 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $1.69 | +610.06% | 10 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $2.10 | +852.38% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.10 | +328.57% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 | $73.07 | +12.22% | 15 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 | $8.47 | +1,316.60% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.57 | +955.04% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.72 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.84 | +422.96% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $10.36 | +141.31% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.32 | +417.24% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $26.83 | +675.25% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.95 | +1,589.01% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $10.92 | +724.18% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $5.00 | -20.00% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $4.81 | +523.70% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $13.92 | +29.31% | 1 | Oct 27, 2020 |
Lexeo Therapeutics
Oct 7, 2025
Maintains: Buy
Price Target: $15 → $17
Current: $8.24
Upside: +106.31%
Palvella Therapeutics
Sep 26, 2025
Maintains: Buy
Price Target: $60 → $73
Current: $69.90
Upside: +4.43%
Immuneering
Sep 26, 2025
Maintains: Buy
Price Target: $13 → $20
Current: $6.13
Upside: +226.26%
Krystal Biotech
Aug 22, 2025
Maintains: Buy
Price Target: $219 → $216
Current: $181.47
Upside: +19.03%
Rocket Pharmaceuticals
Aug 20, 2025
Maintains: Buy
Price Target: $11
Current: $3.42
Upside: +221.64%
Metagenomi
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $2.86
Upside: +284.62%
Solid Biosciences
Aug 14, 2025
Maintains: Buy
Price Target: $15
Current: $5.96
Upside: +151.68%
Taysha Gene Therapies
Aug 12, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $4.88
Upside: +104.92%
4D Molecular Therapeutics
Aug 12, 2025
Maintains: Buy
Price Target: $25
Current: $8.90
Upside: +180.90%
Intellia Therapeutics
Aug 11, 2025
Maintains: Buy
Price Target: $68 → $60
Current: $24.52
Upside: +144.70%
Aug 8, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $5.68
Upside: +76.06%
Aug 8, 2025
Maintains: Buy
Price Target: $12
Current: $1.69
Upside: +610.06%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $2.10
Upside: +852.38%
Aug 7, 2025
Maintains: Buy
Price Target: $9
Current: $2.10
Upside: +328.57%
Aug 5, 2025
Maintains: Buy
Price Target: $82
Current: $73.07
Upside: +12.22%
Jun 24, 2025
Maintains: Buy
Price Target: $120
Current: $8.47
Upside: +1,316.60%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.57
Upside: +955.04%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.72
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.84
Upside: +422.96%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $10.36
Upside: +141.31%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $2.32
Upside: +417.24%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $26.83
Upside: +675.25%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.95
Upside: +1,589.01%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $10.92
Upside: +724.18%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $5.00
Upside: -20.00%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $4.81
Upside: +523.70%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $13.92
Upside: +29.31%